Method for the production of collagen in vivo and in vitro using nanoparticles carrying messenger RNA
mRNA-carrying nanoparticles address inefficiencies in collagen production by enabling efficient collagen synthesis in vivo and in vitro, improving skin structure and healing through collagen replenishment and tissue renewal.
Patent Information
- Application Number
- PCT/BR2026/050213
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-07
- Filing Date
- 2026-05-07
- Publication Date
- 2026-11-12
AI Technical Summary
Existing methods for producing collagen, such as extraction from animal tissues, genetic engineering, and precision fermentation, face challenges like low efficiency, high cost, contamination risks, and bioethical concerns, while mRNA-based systems for collagen delivery lack specific formulations for type III collagen in collagen replacement therapy.
Development of mRNA-carrying nanoparticles, encapsulating collagen-encoding mRNA, optionally with hyaluronate synthase and RNAi for collagenase, using metallic or lipid nanoparticles for efficient collagen production in vivo and in vitro, promoting collagen replenishment and tissue healing.
Facilitates rapid, safe, and efficient collagen production in vivo and in vitro, enhancing skin structure, hydration, and healing, with applications in regenerative medicine and anti-aging therapies.
Smart Images

Figure BR2026050213_12112026_PF_FP_ABST
Abstract
Description
METHOD FOR PRODUCING COLLAGEN IN VIVO AND IN VITRO VIA MESSENGER RNA CARRIER NANOPARTICLES - TECHNOLOGICAL SECTOR OF THE INVENTION
[0001] The present invention is situated in the field of biotechnology and relates to the development of messenger RNA (mRNA) carrier nanoparticles and methods for the production of collagen, preferably type III collagen, in vivo and in vitro, for application in the cosmetic and / or therapeutic area of collagen replacement in human and animal skin; but not limited only to type III collagen, and may include type I and II collagen, with or without the addition of mRNA for the production of the enzyme hyaluronate synthase (HAS) or RNA interference (RNAi) for the enzyme collagenase.
[0002] The present invention also comprises methods for producing mRNA and encapsulating it in nanoparticles for efficient transfection of human and animal cells, using advanced in vitro transcription techniques based on linearized DNA templates, ensuring high purity and efficiency in in situ protein expression. STATE OF THE ART
[0003] Collagen is an essential structural protein found in mammalian connective tissues, widely distributed in the extracellular matrix and playing an important biological role in tissue formation, organ support, body protection, tissue repair, and signaling. Due to its functional properties, as well as physical properties as a stabilizing and emulsifying agent, and being a protein source, collagen has been used in various industrial applications, including the biomedical, food, and cosmetics industries (Ahmad et al., 2024; Knychala et al., 2024).
[0004] Collagen consists of a family of fibrous proteins, formed by three polypeptide chains, which may be identical or different, characterized by the presence of domains of varying lengths of the tripeptide unit (Glycine-XY)n, where X and Y can be any amino acid, but generally X is glycine and Y is hydroxyproline or hydroxylysine. The three chains join in a triple helix forming the structure of procollagen, which subsequently undergoes a series of post-translational processes, generating the mature collagen molecule (Ahmad et al., 2024; Gomes et al., 2022).
[0005] Approximately 28 distinct collagen isoforms are described in the literature. Type I collagen is the predominant form in most tissues, including the skin, while type III collagen, although present in smaller quantities, plays an essential role in maintaining tissue integrity and controlling the healing process (Cao et al., 2024).
[0006] Traditional methods for obtaining collagen involve extraction from animal tissues (Bhuimbar et al., 2019), genetic engineering techniques based on cell culture, and precision fermentation for the production of recombinant protein, as detailed in Li et al., 2015; Xiang et al., 2022, and in patent BR 102018015599-7 - YEAST STRAIN, METHOD FOR PRODUCING COLLAGEN, MULTIFUNCTIONAL VECTOR, AND CHIMERIC COLLAGEN DNA SEQUENCE, owned by MODERN MEADOW, INC. However, these processes present challenges such as low efficiency, high cost, risk of contamination, and bioethical limitations.
[0007] mRNA technology has been extensively studied as an innovative alternative for in vivo protein expression. mRNA-based systems offer advantages such as high biosafety, absence of genomic integration, and rapid and efficient production of desired proteins. Advanced techniques described in the literature (You et al., 2022), as well as those detailed in patents for vaccines against SARS-CoV-2 virus, such as WO2023147092, demonstrate the potential for their application in the cosmetic and gene therapy fields, respectively, with their efficacy validated globally during vaccination against SARS-CoV-2 virus.
[0008] You et al., (2023) described a therapy based on the use of exosome-containing mRNA encoding type I collagen (COL1A1) to replace dermal collagen protein loss as an anti-aging treatment for photoaging skin, using an acute photoaging model in mice that mimics the pathophysiological characteristics of age-damaged skin in humans. To improve the efficiency of mRNA delivery and retention, collagen mRNA delivery is achieved through a hyaluronic acid (HA) microneedle patch (COL1A1-EV MN) that allows for more efficient mRNA distribution in the dermis, resulting in durable collagen protein engraftment and improved wrinkle treatment in photoaged skin.
[0009] Patent document WO1999060167 - COMPOSITIONS AND METHODS FOR TOPICAL DELIVERY OF OLIGONUCLEOTIDES refers to compositions and methods for the topical delivery of nucleic acids to the epidermis, dermis and their layers in animals. More particularly, the invention is directed to the use of liposomes and penetration enhancers to effect the transport of oligonucleotides and other nucleic acids to the epidermis and dermis.
[0010] Patent document W02016131052 - NUCLEIC ACID PRODUCTS AND METHODS OF ADMINISTRATION THEREOF refers, in part, to methods, compositions and products for producing and delivering nucleic acids to cells, tissues, organs and patients; methods for expressing proteins in cells, tissues, organs and patients; and therapeutic and cosmetic products produced using these methods, compositions and products. In a specific aspect of the invention, the administration of synthetic RNA comprising canonical and non-canonical nucleotides encoding collagenase as an anti-scarring treatment is discussed.
[0011] Patent document WO2017191274 - RNA ENCODING A THERAPEUTIC PROTEIN provides a suitable system for use in gene therapy. In particular, it provides a system for expressing a therapeutic protein, preferably by stabilizing mRNA and / or increasing the translation efficiency of such mRNA, compared to known nucleic acids in the prior art. It is also an objective of the invention to provide a system that allows the treatment and / or prophylaxis of hereditary or acquired diseases, such as skin and subcutaneous tissue diseases, in a safe and effective manner.
[0012] Patent document WO2019025431 - TREATMENT OF LOCAL SKIN HYPOTROPHY CONDITIONS refers to compositions and methods for treating skin diseases that result in a hypotrophic state ("hypotrophy") of one or more layers of the skin (epidermis, dermis, subcutaneous fat), especially atrophic scars, as medical indications, but also skin conditions that are associated with skin aging, which are generally considered cosmetic problems and areas of interest. In one aspect of the invention, a formulation containing mRNA is provided in which the coding region encodes human FGF, especially human FGF2 or human FGF7, and an acceptable carrier, such as liposomes, lipid nanoparticles, among other acceptable carriers.
[0013] Patent document WO2020227642 - COMPOSITIONS FOR SKIN AND WOUNDS AND METHODS OF USE THEREOF provides methods for: (i) promoting and / or improving wound healing; (ii) preventing and / or reducing scar formation in a wound; (iii) reducing the visibility of a scar; and (iv) treating epidermolysis bullosa in an individual in need thereof, comprising intradermal (e.g., using microneedles) or topical administration of messenger RNA (mRNA) therapeutics, wherein the mRNA encodes a wound-healing polypeptide, and provides a pharmaceutical composition comprising an mRNA encapsulated in lipid nanoparticles comprising an ORF encoding a wound-healing polypeptide, wherein the composition is suitable for intradermal (e.g., using microneedles) or topical administration.The wound-healing polypeptide is selected from the group consisting of a growth factor, a cytokine, a chemokine, a protease inhibitor, and a collagen. The invention also provides a method for treating epidermolysis bullosa in a human individual in need thereof, comprising intradermal or topical administration to a blister or skin erosion of an effective amount of a pharmaceutical composition comprising an mRNA encoding a collagen. In some cases, the collagen is selected from the group consisting of collagen type III, collagen type IV, collagen type V, collagen type VI, collagen type VII, collagen type VIII, collagen type XII, collagen type XIII, collagen type XIV, collagen type XVI, collagen type XVII, collagen type XVIII, collagen type XIX, and collagen type XXVIII.
[0014] Although the aforementioned patents already reveal the use of liposomes containing mRNA for delivery of mRNA to cells and tissues, leading to the in situ synthesis of the protein of interest, none of the documents disclosed the specific association of the formulation of a metallic or lipid nanoparticle containing mRNA that encodes type III collagen in a collagen replacement therapy in human and / or animal skin.
[0015] Another document of particular relevance to the present invention is patent BR 102015021451-0 - MAGNETIC NANOPARTICLES WITH DOUBLE COATING FOR CARRYING NUCLEIC ACIDS AND POLYANIONIC MOLECULES IN VITRO AND IN VIVO. This refers to magnetic field-responsive nanoparticles for the complexation, accumulation, transfection, and controlled release of bioactive molecules such as nucleic acids and polyanions, in vitro or in vivo. The present invention describes metallic nanoparticles containing iron oxide, calcium phosphate, and polyanionic molecules and an outer layer of PEG-Asp copolymer (polyethylene glycol and polyaspartate), as described in BR 102015021451-0. A partnership agreement between the holders of the aforementioned Patent BR 102015021451-0 and the holders of the present invention was established for the development of the new nanoparticle, which differs from BR 102015021451-0 by carrying larger nucleic acid molecules, such as mRNA molecules, for the purpose of in vivo and in vitro collagen expression with application in the field of collagen replacement therapy in the skin.Furthermore, other examples of particle coating include, but are not limited to, polymers such as PEG (polyethylene glycol), PVP (polyvinylpyrrolidone), and copolymers such as PLGA (polylactic acid and polyglycolic acid), as well as chitosan coating (a natural polymer derived from chitin). The use of chitosan in the coating of magnetic nanoparticles contributes to greater adhesion to the skin and / or tissues and to therapeutic properties associated with healing, antimicrobial and antioxidant action (Amor et al., 2023).
[0016] In view of this, the present invention describes a novel method for in situ collagen production mediated by the use of mRNA-carrying nanoparticles encoding human collagen III, but not limited to collagen type III, and may include other collagen types such as collagen types I and II. In the target cells, the endocytosed nanoparticle releases its mRNA payload, which is then translated into the protein of interest, collagen, using the cellular machinery. The increased expression of collagen in the target cells, for example in the skin, contributes to collagen replenishment in the skin, better structural support and hydration, helping to combat aging, as well as accelerating tissue healing in the case of injuries.
[0017] In another aspect, the present invention describes the use of ribonucleic acid (RNA) carrier nanoparticles containing combined forms of mRNA encoding for collagen associated with mRNA encoding for the production of the enzyme hyaluronate synthase (HAS) and / or RNA interference (RNAi) for the enzyme collagenase. The combination of different payloads on the nanoparticle can be used as a way to enhance the tissue renewal effect. The hyaluronate synthase enzyme is responsible for the polymerization of hyaluronic acid, a glycosaminoglycan that constitutes one of the main components of the extracellular matrix of connective tissues, such as the skin. In the area of cosmetics and tissue regeneration, hyaluronic acid plays an important role in skin homeostasis and repair, promoting hydration, cell migration, angiogenesis, and modulation of the inflammatory response during tissue regeneration (Jiang et al., 2007; Valachová et al., 2024).Silencing the expression of the collagenase enzyme via RNAi aims to reduce the excessive degradation of collagen, especially collagen types I, II, and III, associated with the skin aging process. SUMMARY OF THE INVENTION
[0018] The present invention describes an mRNA-carrying nanoparticle for the production of collagen in vivo or in vitro, designed to optimize mRNA delivery to target cells in order to promote efficient collagen expression. Said mRNA molecule has a coding sequence that translates to the expression of human collagen III. In other embodiments, sequences of other collagen types (types I to XX), pro-collagens, and truncated forms may be employed.
[0019] In another aspect, the present invention describes the use of ribonucleic acid (RNA) carrier nanoparticles containing combined forms of mRNA encoding for collagen associated with mRNA encoding for the production of the enzyme hyaluronate synthase (HAS) and / or RNA interference (RNAi) for the enzyme collagenase. The combination of different payloads on the nanoparticle can be used as a way to enhance the tissue renewal effect.
[0020] The present invention also comprises a process for producing mRNA in vitro and its delivery and / or encapsulation in nanoparticles.
[0021] One aspect of the invention relates to the composition of the nanoparticles, which can be metallic in nature, including materials such as iron oxide, calcium phosphate, polyanionic molecules, and an outer copolymer layer. In another embodiment, lipid nanoparticles containing structural lipids, ionizable lipids, cholesterol, and lipids conjugated with polyethylene glycol can be used.
[0022] The proposed technology allows for the rapid and safe production of collagen in vitro and in vivo, with applications in regenerative medicine in humans and animals, anti-aging therapies, and biomaterials. BRIEF DESCRIPTION OF THE ATTACHED DRAWINGS
[0023] In order for the present invention to be fully understood and put into practice by any technician in a compatible technological field, it is described in a clear, concise and sufficient manner, based on the attached drawings, which illustrate and support it, listed below: Figure 1 presents the flowchart with the steps of the process for obtaining mRNA-carrying nanoparticles, including synthesis by in vitro transcription and encapsulation in nanoparticles (NPs) for subsequent use in target cells, with the aim of increasing collagen production in the respective cells. Figure 2 presents a representation of a synthetic plasmid DNA template designed to be used, after linearization, in the synthesis of mRNA encoding human collagen III protein. Figure 3 shows an example of the process of mRNA production by in vitro transcription. DETAILED DESCRIPTION OF THE INVENTION
[0024] The method of producing collagen in vivo and in vitro via messenger RNA-carrying nanoparticles. The invention presented in this patent proposes a new process for the production of collagen in vivo or in vitro through the administration of mRNA-carrying nanoparticles. Messenger RNA (mRNA) is a type of ribonucleic acid molecule responsible for transporting genetic information from DNA (deoxyribonucleic acid) to the ribosomes where it will be translated into the corresponding protein.
[0025] In the present invention, the nanoparticle payload is a nucleic acid sequence, specifically mRNA, encoding for the expression of collagen protein. The term "collagen" refers to any of the known collagen types, Type I to XX, preferably human type III, as presented in SEQ ID N: 1 (COL3A), and also includes its precursor forms (pro-collagens) and truncated variants. However, the invention is not limited to human collagen products and expression and may include variant sequences from other species, such as bovine, equine, porcine, chicken, fish, canine, and feline collagens.
[0026] The invention also includes the use of sequences that encode one or more types of collagen.
[0027] In another embodiment, the nucleic acid molecules comprise COL3A mRNA and a non-COL3A mRNA molecule in combination.
[0028] In another embodiment, the nucleic acid molecules comprise COL3A mRNA and an mRNA molecule encoding the enzyme hyaluronate synthase (encoded by the HAS1, HAS2, and HAS3 genes in humans) in combination, whose protein sequence is exemplified in SEQ ID N: 2 (HAS2).
[0029] In another embodiment, the nucleic acids comprise COL3A mRNA and additionally RNAi (RNA interference) for silencing the expression of the collagenase enzyme, according to the target sequence of the metallopeptidase 1 enzyme (MMP-1) exemplified in SEQ ID N:3. Oligonucleotides for RNAi production contain a specific region of MMP-1 mRNA (SEQ ID N: 3), but are not limited to this sequence, an internal loop, and 5' and 3' ends for subcloning into vectors of interest for in vitro transcription.
[0030] Figure 1 presents the flowchart with the steps of the process. For the production of mRNA via in vitro transcription, a linearized plasmid containing the template DNA sequence or a linear fragment amplified by PCR (Polymerase Chain Reaction) can be used. The process can be subdivided into three steps, as follows: A. Step 1 i. Construction of the plasmid containing the gene of interest through cloning or gene synthesis; ii. Plasmid amplification in E. coli iii. Purification and linearization of DNA with restriction enzymes; iv. Alternatively, the sequences of interest can be obtained by PCR, generating a fragment that is already linear. B. Stage 2 i. In vitro transcription through enzymatic reaction with RNA polymerase enzyme, such as the RNA polymerase enzyme of bacteriophage T7, under suitable conditions and in the presence of triphosphate nucleotides; ii. 5' Capping - A step involving the addition of a 7-methylguanosine cap to the 5' end of mRNA is performed simultaneously with transcription using cap analogs or can be introduced post-transcriptionally using specific capping enzymes. This modification is important to ensure mRNA stability and translation efficiency; iii. Poly-A tail addition. When not present in the plasmid vector sequence used as a template, the poly-A tail can be added after the in vitro transcription event. iv. Digestion of the template DNA with DNase I; v. Purification of RNA through chromatography or the use of specific kits, followed by a sterilization process. C. Stage 3 i. Encapsulation of RNA in nanoparticles; ii. Dilution and sterilization by filtration.
[0031] Figure 2 presents an example of a plasmid vector containing the synthetic template DNA sequence described in SEQ ID N: 4. This sequence includes the promoter region, the Kozak sequence, the ORF of interest (in this case, the COISA gene), and the poly-A tail. In another embodiment, mRNA is produced via in vitro transcription using a single plasmid containing two or more ORFs of interest. Multiple incorporated genes improve the potential for protein expression, ensuring greater consistency and reducing the number of transfection events. The in vitro transcription step follows standard protocols available in the literature.
[0032] The mRNA of COL3A comprises a nucleotide sequence with 95% to 100% identity to the sequence described in SEQ ID N: 5.
[0033] In some cases, the nucleic acid comprises modifications (substitution, addition, or deletion of nucleotides) in its sequence or the presence of non-canonical modified nucleotides that differ from the standard bases (guanine, cytosine, uracil / thymine, adenine) compared to the original nucleic acid sequence. In another embodiment, the nucleic acid sequence designated in SEQ ID N: 4 comprises modifications in the 5' and 3' UTR regions of the mRNA. In yet another embodiment, the mRNA sequence may be altered through codon optimization without affecting the sequence of the mature protein.
[0034] A "promoter" is understood to be a specific DNA sequence that regulates gene transcription. In the example shown in Figure 3, the T7 promoter sequence (SEQ ID N: 6) was used, which is recognized by the RNA polymerase of bacteriophage T7. Under appropriate in vitro reaction conditions and in the presence of triphosphate nucleotides, a high efficiency of mRNA production is obtained.
[0035] Suitable promoter sequences for regulating in vitro transcription of the target gene in the present invention include, but are not limited to, the T7 promoter (SEQ ID N: 6), the T3 promoter (SEQ ID N: 7), and the SP6 promoter (SEQ ID N: 8).
[0036] Kozak sequence is a sequence located upstream of the initiation codon of the ORF of interest, in the 5' UTR region, which acts as a facilitator for the initiation of translation in eukaryotes. ORF, short for Open Reading Frame, refers to a region of the nucleic acid or mRNA sequence that codes for a polypeptide, beginning with an initiation codon and ending with a termination codon.
[0037] In some cases, mRNA includes a poly-A region that can vary from 10 to 200 nucleotides in length. The poly-A region is present in the plasmid vector used as a template in in vitro transcription, or it can be added in a subsequent step after the in vitro transcription event. This region confers greater stability to the mRNA and protection against degradation.
[0038] The present invention also describes methods for delivering nucleic acid to cells via nanoparticles. The nanoparticles function as delivery vehicles for nucleic acids in vitro or in vivo, enabling the transport of these molecules across the cell membrane via the cellular endocytosis system. Furthermore, they contribute to greater stability and reduced enzymatic degradation of the active molecules. Once inside the cell, the nucleic acid causes changes in the expression levels of the target protein(s).
[0039] Preferably, the present invention describes metallic nanoparticles containing iron oxide, calcium phosphate, and polyanionic molecules and an outer layer of PEG-Asp copolymer (polyethylene glycol and polyaspartate), as described in Patent BR 102015021451-0, which can be guided by an external magnetic field if suitable for the specific application. Iron oxide particles (Fe3O4e v-Fe2O3) offer the advantages of low toxicity, biocompatibility, and biodegradability. As previously mentioned, a partnership agreement between the holders of Patent BR 102015021451-0 and the holders of the present invention was established for the development of the new nanoparticle, which differs from BR 102015021451-0 by carrying larger nucleic acid molecules, such as mRNA molecules, for the purpose of expressing collagen in vivo and in vitro with application in the field of collagen replacement therapy in the skin or even its application in the field of animal cell culture.Furthermore, other examples of particle coating include, but are not limited to, polymers such as PEG (polyethylene glycol), PVP (polyvinylpyrrolidone), and copolymers such as PLGA (polylactic acid and polyglycolic acid) and PEG-Asp (polyethylene glycol and polyaspartate), as well as chitosan coating (a natural polymer derived from chitin). The use of chitosan in the coating of magnetic nanoparticles contributes to greater adhesion to skin and / or tissues and to therapeutic properties associated with healing, antimicrobial and antioxidant action (Amor et al., 2023).
[0040] Alternative nanoparticles can be used for mRNA delivery, such as lipid nanoparticles. In some cases, the lipid nanoparticle comprises structural lipids (5-20%), ionizable lipids (35-60%), cholesterol (30-55%), and lipids conjugated with polyethylene glycol (0.1-3%). In another embodiment, the nanoparticle may be formed by only 2 or 3 of these components. EXAMPLE OF THE PREPARATION OF LIPID NANOPARTICLES CARRYING NUCLEIC ACID
[0041] Lipids, in the correct proportion, are diluted and homogenized in a solvent, generally ethanol, with the pH controlled by the addition of sodium hydroxide (solution A). The mRNA solution is prepared in 10 mM sodium citrate buffer, with the pH adjusted to the range of 4 to 6.5 (solution B). Both solutions (solution A and solution B) are mixed using a microfluidization system or a T-mixer to form nanoparticles with encapsulated mRNA. Ethanol removal is performed by dialysis or ultrafiltration. In another embodiment, the lipids solubilized in ethanol are dried, and the lipid film formed is rehydrated with the mRNA solution under agitation, forming nanoparticles. These can be extruded using a polycarbonate membrane to standardize the size of the nanoparticles.
[0042] It is important to emphasize that the descriptions and Application Forms provided do not limit the methods of execution, modifications, and variations that can be made following the formulations, methodologies, and products of the invention now proposed, but rather illustrate and make understandable the conceptual innovations revealed in this solution. Therefore, the descriptions should be interpreted in an illustrative and non-restrictive manner, and may present variations in the equipment used in the process steps, proportions, dimensions, and other variables, whether of the whole or of its elements individually, provided that their particular characteristics are maintained, and that they are essential to the inventive concept now revealed and do not fall outside the scope of protection outlined in the proposed solution. REFERENCES
[0043] Knychala, M.M.; Boing, L.A.; lenczak, J.L.; Trichez, D.; Stambuk, B.U. Precision Fermentation as an Alternative to Animal Protein, a Review. Fermentation 2024, 10, 315. https: / / doi.org / 10.3390 / fermentation10060315.
[0044] Ahmad, M.I.; Li, Y.; Pan, J.; Liu, F.; Dai, H.; Fu, Y.; Huang, T.; Farooq, S.; Zhang, H. Collagen and gelatin: Structure, properties, and applications in food industry. Int. J. Biol. Macromol. 2024, 254, 128037. [CrossRef],
[0045] Gomes, V., Salgueiro, S.P. From small to large-scale: a review of recombinant spider silk and collagen bioproduction. Discov Mater 2, 3 (2022). https: / / doi.Org / 10.1007 / s43939-022-00024-4.
[0046] Cao L, Zhang Z, Yuan D, Yu M, Min J. Tissue engineering applications of recombinant human collagen: a review of recent progress. Front Bioeng Biotechnol. 2024; 12: 1358246. Published 2024 Feb 14. doi: 10.3389 / fbioe.2024.1358246.
[0047] Li, L.; Fan, D.; Ma, X.; Deng, J.; He, J. High-level secretory expression and purification of unhydroxylated human collagen a1 (III) chain in Pichia pastoris GS115. Biotechnol. Appl. Biochem. 2015, 62, 467-475.
[0048] Xiang, Z.X.; Gong, J.S.; Shi, J.H.; Liu, C.F.; Li, H.; Su, C.; Jiang, M.; Xu, Z.H.; Shi, J.S. High-efficiency secretory expression and characterization of the recombinant type III human-like collagen in Pichia pastoris. Bioresour. Bioprocess. 2022, 9, 117.
[0049] Bhuimbar MV, Bhagwat PK, Dandge PB. Extraction and characterization of acid soluble collagen from fish waste: development of collagen-chitosan blend as food packaging film. J Environ Chem Eng. 2019;7(2): 102983.
[0050] Amor IB, Emran TB, Hemmami H, Zeghoud S, Laouini SE. Nanomaterials based on chitosan for skin regeneration: an update. Int J Surg.2023 Mar 1 ;109(3):594-596. doi: 10.1097 / JS9.0000000000000181. PMID: 36912528; PMCID: PMC10389491.
[0051] You, Y. et al.; Intradermally delivered mRNA encapsulating extracellular vesicles for collagen-replacement therapy. Nature Biomedical Engineering, Vol. 7, p. 887- 900, July 2023.
[0052] Valachová, K.; Hassan, M.E.; Soltés, L. Hyaluronan: Sources, Structure, Features and Applications. Molecules 2024, 29, 739.
[0053] Jiang, D., Liang, J., & Noble, P. W. (2007). Hyaluronan in Tissue Injury and Repair. Annual Review of Cell and Developmental Biology, 23(1 ), 435-461. doi: 10.1146 / annurev.cellbio.23.09050
Claims
CLAIMS 1. METHOD OF IN VIVO AND IN VITRO COLLAGEN PRODUCTION VIA MESSENGER RNA CARRIER NANOPARTICLES characterized by the nanoparticle's payload being a nucleic acid sequence, specifically mRNA, encoding the expression of collagen protein, Type I to XX, preferably human Type III, containing a nucleotide sequence with 95% to 100% identity to the sequence presented in SEQ ID N: 5; and by using a linearized plasmid containing the template DNA sequence (SEQ ID N: 4) or a linear fragment amplified by PCR (Polymerase Chain Reaction) for mRNA production via in vitro transcription, and by the method following the sequential steps: A. Stage 1: i. Construction of the plasmid containing the gene of interest through cloning or gene synthesis; ii. Plasmid amplification in E. coli iii. Purification and linearization of DNA with restriction enzymes; B. Stage 2: i. In vitro transcription through enzymatic reaction with RNA polymerase enzyme, such as the RNA polymerase enzyme of bacteriophage T7, under suitable conditions and in the presence of triphosphate nucleotides; ii. 5' Capping - A step of adding a 7-methylguanosine cap to the 5' end of mRNA is performed simultaneously with transcription using cap analogs or can be introduced post-transcriptionally using specific capping enzymes; iii. Poly-A Tail Addition - When not present in the sequence of the plasmid vector used as a template, the poly-A tail can be added after the in vitro transcription event. iv. DNA digestion with DNase I; v. Purification of RNA through chromatography or the use of specific kits, followed by a sterilization process; C. Step 3: i. Encapsulation: NP + RNA formulation; ii. Dilution and sterilization by filtration.
2. METHOD FOR PRODUCING COLLAGEN IN VIVO AND IN VITRO VIA MESSENGER RNA CARRIER NANOPARTICLES, according to claim 1, characterized in that the nanoparticle cargo also includes its precursor forms, pro-collagens, and truncated variants.
3. METHOD FOR PRODUCING COLLAGEN IN VIVO AND IN VITRO VIA NANOPARTICLES CARRYING MESSENGER RNA, according to claim 1, characterized in that the nanoparticle cargo may include variant collagen sequences from other species, such as bovine, equine, porcine, chicken, fish, canine and feline collagens.
4. METHOD FOR PRODUCING COLLAGEN IN VIVO AND IN VITRO VIA MESSENGER RNA CARRIER NANOPARTICLES, according to claim 1, characterized in that the nanoparticle cargo is nucleic acid molecules comprising COL3A mRNA, presented in SEQ ID N: 1, and a non-COL3A mRNA molecule in combination.
5. METHOD FOR PRODUCING COLLAGEN IN VIVO AND IN VITRO VIA MESSENGER RNA CARRIER NANOPARTICLES, according to claim 1, characterized in that the nanoparticle cargo is nucleic acid molecules comprising COL3A mRNA, shown in SEQ ID N: 1, and an mRNA molecule encoding the hyaluronate synthase enzyme, encoded by the HAS1, HAS2 and HAS3 genes in humans, in combination, whose protein sequence is exemplified in SEQ ID N: 2 (HAS2).
6. METHOD FOR PRODUCING COLLAGEN IN VIVO AND IN VITRO VIA MESSENGER RNA CARRIER NANOPARTICLES, according to claim 1, characterized in that the nanoparticle cargo is nucleic acid molecules comprising COL3A mRNA, presented in SEQ ID N: 1, and additionally RNAi, according to the target sequence of the metallopeptidase 1 enzyme (MMP-1) exemplified in SEQ ID N:
3.
7. METHOD FOR PRODUCING COLLAGEN IN VIVO AND IN VITRO VIA MESSENGER RNA CARRIER NANOPARTICLES, according to claim 1, characterized in that the nanoparticle cargo is nucleic acid molecules comprising COL3A mRNA, presented in SEQ ID N: 1, in combination with an mRNA molecule encoding the hyaluronate synthase enzyme, encoded by the HAS1, HAS2 and HAS3 genes in humans, in combination, whose protein sequence is exemplified in SEQ ID N: 2 and RNAi, according to the target sequence of the metallopeptidase 1 enzyme (MMP-1) exemplified in SEQ ID N:
3.
8. METHOD FOR PRODUCING COLLAGEN IN VIVO AND IN VITRO VIA MESSENGER RNA CARRIER NANOPARTICLES, according to claim 1, characterized by the plasmid vector used in Step Ai containing the synthetic template DNA sequence described in SEQ ID N:
4.
9. METHOD FOR PRODUCING COLLAGEN IN VIVO AND IN VITRO VIA MESSENGER RNA CARRIER NANOPARTICLES, according to claim 1, characterized in that mRNA is produced via in vitro transcription via a single plasmid containing 2 or more ORFs of interest.
10. METHOD FOR PRODUCING COLLAGEN IN VIVO AND IN VITRO VIA MESSENGER RNA CARRIER NANOPARTICLES, according to claim 1, characterized in that the nucleic acid comprises modifications, substitution, addition or deletion of nucleotides in its sequence or includes the presence of non-canonical modified nucleotides that differ from the standard bases guanine, cytosine, uracil / thymine, adenine, compared to the original nucleic acid sequence.
11. METHOD FOR PRODUCING COLLAGEN IN VIVO AND IN VITRO VIA MESSENGER RNA CARRIER NANOPARTICLES, according to claim 1, characterized by the mRNA being able to have its sequence altered through codon optimization, without affecting the sequence of the mature protein. 12 METHOD FOR PRODUCING COLLAGEN IN VIVO AND IN VITRO VIA MESSENGER RNA CARRIER NANOPARTICLES, according to claims 1 and 6, characterized by the nucleic acid sequence designated in SEQ ID N: 4 comprising modifications in the 5' and 3' UTR region of mRNA. 13 METHOD FOR PRODUCING COLLAGEN IN VIVO AND IN VITRO VIA MESSENGER RNA CARRIER NANOPARTICLES, according to claim 1, characterized by the promoter sequences suitable for regulating in vitro transcription of the target gene being promoter T7, as per SEQ ID N: 6, promoter T3, as per SEQ ID N: 7, and promoter SP6, as per SEQ ID N:
8.
14. METHOD FOR PRODUCING COLLAGEN IN VIVO AND IN VITRO VIA MESSENGER RNA CARRIER NANOPARTICLES, according to claim 1, characterized by the nanoparticle coating being polymers such as PEG (polyethylene glycol), PVP (polyvinylpyrrolidone), and copolymers such as PLGA (polylactic acid and polyglycolic acid) and also a chitosan coating. 15 METHOD FOR PRODUCING COLLAGEN IN VIVO AND IN VITRO VIA MESSENGER RNA CARRIER NANOPARTICLES, according to claim 1, characterized in that the nanoparticle is a lipid nanoparticle comprising 5 to 20% structural lipids, 35 to 60% ionizable lipids, 30 to 55% cholesterol and 0.1 to 3% lipids conjugated with polyethylene glycol.
